Treatments for ADHD

For adults with ADHD, stimulant medication is the first-line treatment according to all major national and international clinical guidelines. These medications are among the most effective treatments in psychiatry and lead to meaningful symptom improvement in approximately 70–90% of patients. When appropriately prescribed and monitored, stimulant medications are generally safe, well tolerated, and effective across a wide range of ADHD presentations.

These medication are sometimes misleadingly named as ‘ stimulants’ . Rather than “stimulating” the individual, they are better understood as dopamine normalisers. They increase but normalise dopamine and noradrenaline availability in specific brain networks involved in attention, executive functioning, motivation, and emotional regulation because there is clear evidence of low dopamine availability in these areas. In majority of people with ADHD, this typically results in improved focus, calmer thinking, and greater emotional stability, rather than over-stimulation or euphoria.

There are two main stimulant groups used in the UK and internationally: methylphenidate-based medications and dexamphetamine-based medications. Both groups are available in long-acting and short-acting formulations, allowing treatment to be tailored to individual needs, symptom patterns, and daily routines.

Long-acting stimulants, also referred to as modified-release or slow-release preparations, typically begin working within 40 minutes to one hour and last between 8 and 14 hours. Common examples of long-acting methylphenidate include Concerta XL and Medikinet XL. Long-acting dexamphetamine formulations include lisdexamfetamine, commonly known as Elvanse (or Vyvanse in the USA, Canada, and Australia), and Adderall XR in North America.

Short-acting stimulants, also known as immediate-release or quick-release preparations, usually start working within around 20 minutes and last approximately 3 to 5 hours. Examples include Ritalin or generic methylphenidate for the methylphenidate group, and Amfexa or Waymade for dexamphetamine.

There can be significant variation in both effectiveness and side-effects between different brands, even when they contain the same active medication. Individual responses are influenced by absorption rates, release mechanisms, metabolism, and personal neurobiology.

At present, there is no reliable way to predict whether methylphenidate or dexamphetamine will be the most effective medication for a particular individual. As a result, a carefully monitored trial-and-error approach, guided by patient experience and preference, remains the most effective strategy. No medication or brand is universally superior, and once an effective and well-tolerated option is identified, it is generally advisable not to switch unnecessarily.

Long-acting medication is often preferred for convenience, smoother symptom control, and reduced stigma during the day. However, some individuals benefit from additional short-acting doses, particularly early in the morning or later in the evening, depending on their daily demands.

Dexamphetamine is pharmacologically slightly more potent than methylphenidate, as it increases dopamine through two complementary mechanisms, whereas methylphenidate acts primarily through one. For this reason, typical maximum daily doses differ, with dexamphetamine usually prescribed up to around 60–70 mg per day, and methylphenidate up to around 100 mg per day. These limits are guidelines rather than absolute thresholds, and some individuals with shorter duration of benefit may require higher or more frequent dosing under specialist supervision.

Table comparing short and log acting stimulants

Most side-effects associated with stimulant medication are mild, predictable, and temporary, particularly during the early stages of treatment or during dose adjustments. These may include a slight increase in heart rate or blood pressure, feelings of tension or overstimulation, difficulty sleeping if medication is taken too late in the day, reduced appetite or mild weight loss, and dry mouth. In most cases, these effects settle with time or dose adjustment.

No. ADHD stimulant medications are not addictive when used appropriately.

Are stimulants like speed or cocaine?

Confusion arises because stimulant medications act on very similar brain pathways and neurotransmitter systems as street drugs such as cocaine and methamphetamine, particularly within dopamine-rich regions of the brain. However, prescription stimulant medications are manufactured specifically in very small, precise, and predictable doses, designed for therapeutic use rather than intoxication. In individuals with ADHD — who are known to have lower baseline dopamine activity in certain brain networks — stimulants rarely cause significant euphoria, elation, or a “high”. Instead, they typically produce a calming, focusing, and emotionally stabilising effect, rather than a stimulating one.

Will I need to be on medication all my life?

ADHD medications rebalance dopamine signalling but do not reverse the underlying neurodevelopmental differences. This means medication usually needs to be taken regularly throughout ones life, in a similar way to treatments for long-term medical conditions such as diabetes or hypertension. This represents appropriate medical reliance, not addiction.

Importantly, untreated ADHD is strongly associated with self-medication using alcohol, cocaine, excessive caffeine, sugar, or cannabis. These substances are far more harmful and unpredictable. Once ADHD is appropriately treated with medication, substance misuse often reduces substantially.

Are they misused by students?

Concerns about “student misuse” are frequently overstated. Research suggests that many individuals who use stimulant medication without prescriptions actually meet criteria for previously undiagnosed ADHD.

Will I have withdrawal symptoms if I stop the medication?

When stimulant medication is stopped — or occasionally when its effects wear off — some patients may notice temporary fatigue, irritability, or low energy. This is usually mild, short-lived, and not a true withdrawal syndrome. In most cases, it reflects a brief return of pre-treatment ADHD symptoms that feel more noticeable after improvement. Hence, withdrawal symptoms are uncommon and, when present, are usually very mild.

Non-stimulant medications are typically used when stimulants are not tolerated, when there is significant substance misuse, or when medical conditions contraindicate stimulant use. They can be prescribed either alone or in combination with stimulant medication.

When used on their own, non-stimulant medications have a lower overall efficacy, with symptom improvement seen in approximately 40–60% of patients, compared with 70–90% for stimulants. For this reason, unless contraindicated, it is usually appropriate to trial at least one medication from each stimulant group before moving to non-stimulant options.

Atomoxetine may cause side-effects such as increased heart rate or blood pressure, nausea, gastrointestinal discomfort, sleep disturbance, or irritability. Guanfacine may lead to tiredness, dizziness, low blood pressure, headaches, or abdominal discomfort. These effects are often dose-dependent and may improve with time.

Bupropion is an antidepressant with some evidence of benefit in ADHD due to its dopaminergic effects. In the UK, it is licensed for smoking cessation, but it is licensed for depression and used more broadly in countries such as the USA and Canada.

Modafinil is a wakefulness-promoting medication used primarily for narcolepsy and daytime sleepiness. While it has stimulant-like properties, it is generally less effective for core ADHD symptoms.

Historically, antidepressants acting on noradrenaline systems, such as venlafaxine, clonidine, and imipramine, have shown some benefit in ADHD, but they are not routinely used in modern practice.

Psychological therapies are usually most effective after medication has improved attention, emotional regulation, and cognitive flexibility. Without this foundation, many individuals with ADHD struggle to engage fully with therapy, particularly approaches that rely on sustained focus, emotional reflection, or structured homework.

Cognitive Behavioural Therapy (CBT) can be helpful for addressing negative thinking patterns, low self-esteem, procrastination, and organisational difficulties. However, in ADHD its benefits are often limited if core attentional and regulatory difficulties remain untreated. When used after or alongside medication, CBT can be far more effective in helping people develop insight, challenge long-standing self-critical beliefs, and build practical coping strategies.

Dialectical Behavioural Therapy (DBT), originally developed for emotional instability, is increasingly recognised as valuable in ADHD. Its emphasis on emotional regulation, distress tolerance, impulse control, and interpersonal effectiveness makes it particularly well suited to adults with ADHD, especially those with significant emotional dysregulation or rejection sensitivity. The skills-based, practical nature of DBT is often easier for people with ADHD to engage with than purely insight-based therapies.

Eye Movement Desensitisation and Reprocessing (EMDR) was initially developed for trauma-related disorders. Emerging evidence suggests it may also be helpful for individuals with ADHD who have co-existing trauma histories or significant emotional dysregulation, particularly where past experiences continue to amplify emotional responses in the present.

Supportive counselling, psychoeducation, and ADHD coaching are also highly valuable. These approaches focus on practical support: helping individuals organise their lives, manage work demands, prioritise tasks, develop routines, and reflect on long-standing difficulties once cognitive overload has reduced. For many people, this combination of medication and practical psychological support is transformative.

Neurofeedback and neuromodulation techniques are best understood as experimental rather than established treatments for ADHD. Neurofeedback involves training individuals to alter brainwave activity using real-time EEG feedback, with the aim of improving attention and self-regulation. While some individuals report benefit, the overall evidence base remains mixed and inconsistent, with significant variability between studies.

Neuromodulation approaches such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are being actively researched. At present, these techniques are not routinely recommended outside specialist or research settings.

Omega-3 fatty acids have modest evidence for improving attention and hyperactivity, although their effects are small compared to medication. Iron and zinc supplementation may be helpful when deficiencies are present. Other supplements, including magnesium, vitamin D, and various herbal preparations, are sometimes used but have limited and inconsistent supporting evidence.

While several studies have shown promising signals for certain supplements, many trials are small, methodologically weak, or difficult to compare. A major limitation is the lack of standardisation in supplement formulations, doses, and bioavailability, meaning results across studies cannot be reliably combined or generalised. For this reason, supplements should be viewed as adjunctive strategies rather than alternatives to evidence-based treatments and should ideally be discussed with a clinician.

Sleep difficulties are extremely common in ADHD and are often biologically driven, particularly delayed sleep phase and difficulty initiating sleep. Importantly, treating ADHD itself frequently leads to significant improvement in sleep, as delayed sleep onset, fragmented sleep, or poor sleep quality are often secondary to untreated ADHD-related hyperarousal, restlessness, and dysregulated circadian rhythms.

When sleep difficulties persist despite adequate ADHD treatment, non-pharmacological approaches such as Cognitive Behavioural Therapy for Insomnia (CBT-I) should be considered. CBT-I is an evidence-based intervention that helps retrain sleep–wake patterns and address behavioural and cognitive factors that maintain insomnia, and it can be particularly effective when ADHD symptoms are reasonably controlled.

Melatonin is commonly used in ADHD and acts as a chronobiotic rather than a sedative. Its primary role is to help reset or shift the circadian rhythm, especially in individuals with delayed sleep onset. When used correctly (low dose, timed appropriately), it can be very effective and is generally safe.

Low-dose antidepressants (such as trazodone or mirtazapine at low doses) are sometimes used to support sleep, particularly when sleep disturbance co-exists with anxiety or low mood. These are not used to treat depression per se, but for their sedating and sleep-stabilising properties.

Traditional hypnotic sleeping tablets (such as benzodiazepines or Z-drugs) are generally avoided in ADHD due to risks of tolerance, dependence, and worsening emotional regulation over time.

Newer sleep medications, such as daridorexant, act on the orexin system and promote sleep by reducing wakefulness rather than sedation. These may be useful in selected patients, particularly where other approaches have failed, although long-term data in ADHD populations is still emerging.

ADHD symptoms fluctuate with stress, routine disruption, and life events. Flexible, varied work environments tend to suit ADHD better than rigid administrative roles. Many adults with ADHD parent children with ADHD, increasing stress and guilt, making understanding and family support essential.

Medication should usually be taken consistently for at least 6–12 months to allow full assessment of benefit. ADHD medication is safe for long-term use. Some people do find the effect reduces over time but medication never completely stops working (tolerance). Most of the time this tolerance can be explained by worsening of sleep, seasonal impact, hormonal changes, additional stress or anxiety, change of preparation of medication or physical illness. Some times doses need to be increased but most of the time managing these reasons is sufficient.

After fully understanding the impact of medication in all aspects of their lives, some individuals take medication lifelong, while others use it more flexibly once stable.